aripiprazole has been researched along with Chronic Disease in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Bhaskarapillai, B; Chithra, NK; Issac, TG; Kumar, V; Malo, PK; Rao, NP; Reddy, YCJ; Suhas, S | 1 |
| Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y | 1 |
| Adham, N; Banasr, M; Duman, RS; Duric, V; Franklin, T; Gyertyán, I; Kiss, B; Lepack, A | 1 |
| Kar, SK; Srivastava, A | 1 |
| Hebbrecht, K; Morrens, M; Neels, H; Roosens, L; Sabbe, BGC | 1 |
| Pitchot, W | 1 |
| Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ | 1 |
| Adham, N; Gruca, P; Gyertyán, I; Kiss, B; Lasoń-Tyburkiewicz, M; Papp, M | 1 |
| Gorczyca, P; Rykaczewska-Czerwińska, M; Sobiś, J; Świętochowska, E | 1 |
| Bereza, BG; Einarson, TR; Goswami, P; Pudas, H; van Impe, K | 1 |
| Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M | 1 |
| Sikich, L | 1 |
| Gripeos, D; Sokolski, KN | 1 |
| Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Lai, CH | 1 |
| Fujino, J; Tabushi, K; Tanaka, H; Taniguchi, N | 1 |
| Gen, K; Inoue, Y; Suzuki, H | 1 |
| Jean-Baptiste, M; Mukai, Y; Two, A | 1 |
| Carson, WH; Ingenito, GG; Pigott, TA; Saha, AR; Stock, EG; Torbeyns, AF | 1 |
| Duggal, HS | 1 |
| DeQuardo, JR | 1 |
| Goforth, HW; Rao, M; Sucholeiki, R | 1 |
| Fernald, DS; Hovens, JE; Loonen, AJ; van Dellen, RT | 1 |
| Thomas, P | 1 |
| Calais, LA; Cañive, JM; Lundy, SL; Pickard, J; Toney, G; Villarreal, G | 1 |
| Klein, J; Krüger, S; Sarkar, R | 1 |
| Bai, DS; Sea, HS; Seo, WS; Sung, HM | 1 |
4 review(s) available for aripiprazole and Chronic Disease
| Article | Year |
|---|---|
Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials.
Topics: Adult; Aripiprazole; Child; Chronic Disease; Humans; Network Meta-Analysis; Obsessive-Compulsive Disorder; Ondansetron; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2023 |
Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Chronic Disease; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections; Treatment Outcome | 2018 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
7 trial(s) available for aripiprazole and Chronic Disease
| Article | Year |
|---|---|
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Secondary Prevention; Treatment Outcome | 2013 |
Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity.
Topics: Anti-Inflammatory Agents; Aripiprazole; Body Weight; C-Reactive Protein; Chronic Disease; Cytokines; Female; Humans; Insulin; Male; Middle Aged; Schizophrenia | 2015 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Attention; Benzodiazepines; Chronic Disease; Cognition Disorders; Dose-Response Relationship, Drug; Drug Substitution; Executive Function; Female; Humans; Isoindoles; Longitudinal Studies; Male; Memory; Middle Aged; Neuropsychological Tests; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Single-Blind Method; Thiazoles; Time Factors; Verbal Learning | 2011 |
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Double-Blind Method; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2003 |
Prospective study to evaluate the efficacy of aripiprazole as a monotherapy in patients with severe chronic posttraumatic stress disorder: an open trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Combat Disorders; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Personality Assessment; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Stress Disorders, Post-Traumatic; Treatment Outcome; Veterans | 2007 |
Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Tics; Tourette Syndrome; Treatment Outcome | 2008 |
16 other study(ies) available for aripiprazole and Chronic Disease
| Article | Year |
|---|---|
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones; Recurrence; Schizophrenia | 2023 |
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
Topics: Anhedonia; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Aripiprazole; Chronic Disease; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Imipramine; Male; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Receptors, Dopamine D3; Stress, Psychological; Uncertainty | 2017 |
Attributions to new onset catatonic symptoms, late in the course of chronic schizophrenia.
Topics: Amlodipine; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; GABA Modulators; Humans; Hydrochlorothiazide; Lorazepam; Male; Middle Aged; Schizophrenia; Telmisartan; Time | 2017 |
[Is there a place for the physician's hopelesness in the treatment of depression?].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Physician's Role; Piperazines; Quinolones; Remission Induction; Risk Factors; Thiophenes; Treatment Outcome | 2013 |
Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.
Topics: Anhedonia; Animals; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Dietary Sucrose; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Imipramine; Male; Piperazines; Quinolones; Rats, Wistar; Stress, Psychological | 2014 |
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Finland; Humans; Male; Olanzapine; Paliperidone Palmitate; Risperidone; Schizophrenia | 2016 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Markov Chains; Models, Economic; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; State Medicine; United Kingdom | 2015 |
Remission of chronic severe selective serotonin-reuptake inhibitor/selective norepinephrine-reuptake inhibitor refractory depression following adjunctive aripiprazole.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Depression; Drug Therapy, Combination; Female; Humans; Middle Aged; Norepinephrine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2008 |
Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Chronic Disease; Dizziness; Dopamine Agents; Drug Resistance; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Psychiatric Status Rating Scales; Quinolones; Tic Disorders; Treatment Outcome | 2009 |
Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2010 |
Chronic catatonia with obsessive compulsive disorder symptoms treated with lorazepam, memantine, aripiprazole, fluvoxamine and neurosurgery.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Chronic Disease; Combined Modality Therapy; Dopamine Agents; Female; Fluvoxamine; GABA Modulators; Humans; Lorazepam; Memantine; Neurosurgical Procedures; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2011 |
Aripiprazole-induced improvement in tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Psychotic Disorders; Quinolones; Severity of Illness Index | 2003 |
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
Topics: Anger; Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Male; Middle Aged; Paranoid Disorders; Piperazines; Psychomotor Agitation; Quinolones; Schizophrenia | 2004 |
Chronic interictal psychosis responsive to aripiprazole.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Chronic Disease; Clonazepam; Delusions; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Epilepsy, Complex Partial; Epilepsy, Temporal Lobe; Female; Humans; Lamotrigine; Paranoid Disorders; Piperazines; Quinolones; Treatment Outcome; Triazines | 2004 |
Aripiprazole in chronic schizophrenia: experiences in daily practice.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chronic Disease; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors | 2006 |
Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Citalopram; Drug Therapy, Combination; Female; Humans; Middle Aged; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Stereotyped Behavior | 2008 |